{"id":"W3196278183","doi":"10.1007/s10549-021-06334-0","title":"Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population","year":2021,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Tolerability; Letrozole; Internal medicine; Breast cancer; Adverse effect; Neutropenia; Metastatic breast cancer; Population; Oncology; Progression-free survival; Hazard ratio; Cancer; Confidence interval; Chemotherapy; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003720519,0.0008156457,0.0008446689,0.0003176196,0.0006004451,0.0008142968,0.0005915223,0.0007438042,0.01676904],"category_scores_gemma":[0.002100842,0.0003076313,0.0007876434,0.0004135561,0.000349893,0.0004473229,0.0005316227,0.001261335,0.002521585],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000584039,"about_ca_system_score_gemma":0.001369955,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001285204,"about_ca_topic_score_gemma":0.003312651,"domain_scores_codex":[0.9990181,0.0005729375,0.00005056986,0.0001121028,0.0001417655,0.000104519],"domain_scores_gemma":[0.998973,0.0002141808,0.0001432587,0.0001477497,0.000144496,0.000377416],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5422105,0.02028488,0.05170087,0.001731135,0.00356519,0.001185871,0.0004505024,0.002344803,0.05022143,0.000527503,0.08778659,0.2379908],"study_design_scores_gemma":[0.3969037,0.1972301,0.2945009,0.0002388349,0.003391316,0.002091277,0.0001685272,0.001363408,0.008733806,0.0005985677,0.09470806,0.00007145409],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9057022,0.005385989,0.003635207,0.001604368,0.0001977696,0.01487899,0.04572484,0.0006633987,0.02220733],"genre_scores_gemma":[0.8799286,0.00185695,0.005622701,0.002739209,0.0004310872,0.0106347,0.08577372,0.0001813263,0.01283152],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01676904,"threshold_uncertainty_score":0.05609804,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1592860876520025,"score_gpt":0.4842063134928922,"score_spread":0.3249202258408896,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}